5 Things You Didn’t Know about the Hemp Plant

FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.

AHPA, CHPA, CRN, and UNPA say placing ODS under the Office of Nutrition Research would add a layer of bureaucracy. NIH is accepting comments through October 28.

Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.

Clinical research moves beyond compliance, focusing on smarter trial design, risk-based quality, and “evidence engineering” to deliver decisive, decision-ready results.

Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.

DolCas Biotech is featuring the turmeric-derived ingredient Curcugen in Mānukora’s Mānuka honey and Numin’s cognitive-support drink.

The agency’s editorial identifies needs across six areas, including new methods for novel products, gut microbiome data, and AI-supported risk assessment.

The Council for Responsible Nutrition says its Morning Consult survey also found that three in four adults use supplements and that cost is the most commonly cited barrier.